Sanofi Ventures

Name

Sanofi Ventures

Legal name

Sanofi Ventures

Website

https://sanofiventures.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Corporate Venture Capital

NAICS

All Other Financial Investment Activities (52399), Other Financial Investment Activities (5239)

SIC

Finance Services (6199)

akta.pro primary industry

Corporate Strategic Real Assets & Infrastructure Venture Investing (FSANAHAN)

Keywords

• Corporate venture capital
• Early-stage biotech investing
• Digital health investments
• Life sciences venture fund
• Pharma strategic investing

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Equity investment returns: Returns are generated via capital appreciation and exits (IPO, M&A acquisition, strategic buyout by Sanofi or third parties). Examples include Icosavax acquired by AstraZeneca, Aliada Therapeutics acquired by AbbVie for ~$1.4B, Escient Pharmaceuticals acquired by Incyte, Inozyme Pharma acquired by BioMarin, Lumena Pharmaceuticals acquired by Shire, and Curevo agreed to be acquired by Eli Lilly. Several portfolio companies have also reached public markets (Kymera, Icosavax, Ovid Therapeutics, Q32 Bio, Science37).
2. Strategic value capture for parent (Sanofi): Beyond financial returns, the fund generates strategic value by serving as an entry point to the innovation ecosystem for Sanofi, enabling licensing, collaboration, and acquisition of portfolio assets (e.g., Fulcrum-Sanofi losmapimod license, Kymera-Sanofi IRAK4 partnership, i2O-Sanofi nanobody collaboration, Immune Design-Sanofi GLAAS license).

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Sanofi Ventures is the corporate venture capital arm of Sanofi, investing globally in early-stage biotech and digital health companies from Seed to Series B and beyond. The fund provides equity capital alongside select access to Sanofi's scientific, preclinical/clinical development, regulatory, data analytics, manufacturing, market access, and commercialization capabilities, taking board seats and leading financings to build long-term strategic relationships.

Product overview

Sanofi Ventures is the corporate venture capital arm of Sanofi, operating as a single strategic venture fund rather than a software platform with modular products. Its core offering is investment capital paired with strategic support across all stages of the private company lifecycle (Seed to Series B and beyond), delivered alongside select access to Sanofi's expertise in science, preclinical and clinical development, regulatory, data analytics, manufacturing, market access, and commercialization. The portfolio spans more than 80 named companies grouped into two strategic categories: biotherapeutic investments (such as Bionyra, AdvanCell, Abcuro, Diagonal Therapeutics, Korsana Biosciences, Lifordi Immunotherapeutics, Nura Bio, QuantX Biosciences, ReCode Therapeutics, and T-Therapeutics) and digital health investments (such as BranchLab, Carbon Health, Click Therapeutics, Evidation, Medisafe, Omada Health, QuantHealth, and Trial Library). Key portfolio areas of focus include immunology, oncology, rare diseases, vaccines, and digital innovation. The portfolio companies are not Sanofi Ventures' own products but are the named offerings whose success drives the fund's returns, with selected highlights such as BranchLab (AI-native pharma commercialization), QuantHealth (AI-driven clinical trial simulation with digital twins), Click Therapeutics (prescription digital therapeutics), and Empatica (medical-grade wearable patient monitoring) representing the digital health sub-strategy, while Bionyra, Diagonal, Nura Bio, and others anchor the biotherapeutic sub-strategy.

Differentiator

Problem solved

Functional benefit

Products and services

• Sanofi Ventures Strategic Venture Fund

Quantifiable outcome

• $1.4 billion in total fund assets under management
• +3 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Eight partnerships are on record, tiered flagship and core.

• QuantHealthflagshipStrategic or Co-development Partner · 1 October 2025Strategic investment that catalyzed an enterprise strategic relationship supporting Sanofi's focus on integrating advanced AI and digital technologies for drug development. Cris De Luca (Partner at Sanofi Ventures) joined as an observer on QuantHealth's Board. Total QuantHealth funds raised reached $30M; the platform simulates trials using real-world data and AI digital twins with access to 350M+ patient records.
• Fulcrum TherapeuticsflagshipStrategic or Co-development Partner · 13 May 2024Sanofi entered a collaboration and license agreement with Fulcrum for development and commercialization of losmapimod in FSHD (facioscapulohumeral muscular dystrophy). Sanofi received exclusive ex-U.S. commercialization rights; Fulcrum received $80M upfront, up to $975M in potential milestones, plus tiered escalating royalties; parties will share future global development costs 50:50.
• EvidationcoreStrategic or Co-development Partner · 10 January 2022Expanded decade-long collaboration with Sanofi to co-develop unique datasets to understand health in everyday life. Over 20 studies conducted across 10 therapeutic areas (including diabetes and Type 2 Inflammation), more than 500,000 patients reached, and four studies published. Evidation network has 4.4M+ individuals across all 50 U.S. states.
• i2O TherapeuticscoreStrategic or Co-development Partner · 10 February 2021Research collaboration between Sanofi and i2O Therapeutics to investigate oral delivery of Sanofi's Nanobody®-based medicines using i2O's ionic liquid platform. Sanofi Ventures co-led i2O's $4M seed in April 2020 with JDRF T1D Fund; Colorcon Ventures also invested in December 2020.
• Kymera TherapeuticsflagshipStrategic or Co-development Partner · 9 July 2020Multi-program strategic collaboration between Sanofi and Kymera to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in immune-inflammatory diseases plus a second program. Kymera received $150M upfront and may receive more than $2B in potential milestones plus significant royalties; Kymera retains opt-in rights for US cost/profit sharing.
• AetioncoreStrategic or Co-development Partner · 20 November 2019Enterprise-wide collaboration integrating Sanofi's real-world data platform DARWIN with the Aetion Evidence Platform® to advance regulatory submissions using real-world evidence. Aetion is a healthcare technology company backed by NEA, Flare Capital, Lakestar, Town Hall Ventures, McKesson Ventures, Sanofi Ventures, Amgen Ventures, UCB, and Horizon Health Services.
• Science 37coreStrategic or Co-development Partner · 1 March 2017Partnership between Sanofi and Science 37 to develop decentralized, site-less clinical trials using Science 37's Metasite™ model and NORA® technology. Follows Sanofi-Genzyme BioVentures' minority investment in Science 37. Trials using mobile technology and telemedicine to reduce trial time by as much as two years.
• Immune DesigncoreStrategic or Co-development Partner · 16 October 2014Broad collaboration between Sanofi Pasteur and Immune Design for development of a herpes simplex virus (HSV) immune therapy. Sanofi Pasteur contributed HSV-529 and Immune Design contributed G103, leveraging the GLAAS™ platform. Products to be developed jointly through Phase 2. Earlier (Aug 2014), Sanofi licensed Immune Design's GLAAS platform to treat a selected food allergy, with up to $168M in potential milestones plus royalties.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• SR One (GSK): CVC arm of GSK investing in early-stage biotech and digital health. Comparable in mandate, fund structure, and value proposition of bridging startups to a global pharma parent.
• Pfizer Ventures: CVC arm of Pfizer investing in early-stage biotech across multiple therapeutic areas. Comparable structure, mandate, and value proposition of providing strategic capital plus parent R&D access to portfolio companies.
• Eli Lilly (Strategic Investments / Lilly Asia Ventures): Lilly's corporate venture activities focus on biotech and digital health, with significant expansion of private biotech rounds in 2025 (44 total with Sanofi). Most directly comparable as a fellow large pharma CVC ramping activity and competing for similar biotech deal flow.
• Merck Ventures (M Ventures): CVC arm of Merck KGaA investing in biotech and technology platforms. Similar CVC structure with strategic access to parent pharma capabilities and focus on early-stage therapeutic and digital health investments.
• Novartis Venture Fund: Corporate venture capital arm of Novartis investing in early-stage biotech and digital health, with similar strategic-CVC model and global deal sourcing. Most directly comparable as a large pharma CVC with thesis-led investment approach and parent R&D integration.
• Amgen Ventures: CVC arm of Amgen investing in biotech and emerging health technologies. Directly comparable as a strategic CVC with parent R&D and commercial integration.
• Roche Venture Fund: CVC arm of Roche investing in biotech and diagnostics. Comparable in scale and in offering portfolio companies access to parent pharma R&D, manufacturing, and commercial infrastructure, with similar focus on early-stage therapeutic platforms.
• Boehringer Ingelheim Venture Fund (BIVF): CVC arm of Boehringer Ingelheim focused on early-stage biotech and digital health. Comparable CVC structure with similar emphasis on strategic therapeutic alignment and parent partnership pipelines.

Broad incumbents

• RA Capital Management: Healthcare-focused crossover investment fund frequently participating alongside Sanofi Ventures in private biotech rounds (e.g., Diagonal, Memento, Bionyra). Comparable in scale and biotech specialization but structured as a traditional investment firm rather than CVC.
• OrbiMed: One of the largest dedicated healthcare investment firms globally, investing across public and private biotech. While not a CVC, frequently co-invests with Sanofi Ventures and competes for similar biotech deal flow at later stages.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/sanofi

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments123 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanofi Ventures